Does Tigecycline Carry a Risk of Liver Failure?
Tigecycline, an intravenous glycylcycline antibiotic used for complicated infections, has been linked to liver injury, including rare cases of severe hepatic failure. The drug's label warns of potential hepatotoxicity, with post-marketing reports of fatal liver failure, though causation isn't always definitive.[1][2]
What Do Clinical Trials and Labeling Say?
In Phase 3 trials involving over 5,000 patients, elevated liver enzymes (ALT/AST >3x upper limit) occurred in 1-3% of tigecycline users versus <1% in comparators, resolving after discontinuation. Severe cases were rare, but the prescribing information lists 'hepatic failure' under postmarketing adverse events, advising monitoring of liver function in at-risk patients.[1][3]
Real-World Case Reports and Incidence
Post-approval surveillance identified cases of tigecycline-associated acute liver failure, including fatalities. A 2010 review in Drug Safety documented 5 U.S. cases of severe hepatotoxicity, with rapid onset (median 8 days) and high mortality (80%). Incidence remains low—estimated <1:10,000 exposures—but higher in patients with preexisting liver disease or prolonged use.[4][5] FDA's FAERS database logs dozens of hepatic failure reports tied to tigecycline since 2005.[2]
Who’s at Higher Risk?
Patients with chronic liver conditions (e.g., cirrhosis), alcohol use, or concurrent hepatotoxins face elevated risk. Tigecycline is contraindicated in severe hepatic impairment (Child-Pugh C). Combination with other drugs like acetaminophen or valproate amplifies potential for injury via idiosyncratic mechanisms, not clear dose-dependency.[1][6]
How Does Liver Injury from Tigecycline Happen?
The mechanism involves mitochondrial toxicity and oxidative stress, leading to hepatocellular necrosis. Unlike dose-proportional injury from other tetracyclines, tigecycline cases often mimic acute hepatitis with jaundice, coagulopathy, and encephalopathy.[4][7]
Monitoring and Management
Guidelines recommend baseline and periodic LFTs during therapy (up to 14 days). Discontinue if ALT >5x ULN or symptoms like nausea/fatigue appear. No specific antidote exists; supportive care (N-acetylcysteine in some cases) is used. Recovery occurs in survivors upon prompt cessation.[1][3]
Alternatives for Liver-Concerned Patients
For similar infections (e.g., intra-abdominal, skin), options like meropenem or ertapenem have lower hepatotoxicity profiles. Consult infectious disease specialists for high-risk cases.[8]
[1]: Tigecycline Prescribing Information (Pfizer)
[2]: FDA Adverse Event Reporting System (FAERS) Public Dashboard
[3]: Tygacil (tigecycline) Label, DailyMed
[4]: Ganzert M et al., Drug Saf 2010;33(9):755-64 (PubMed)
[5]: FDA MedWatch reports via DrugPatentWatch.com (adverse events summary)
[6]: LiverTox: Tigecycline (NIH)
[7]: Vardakas KZ et al., J Antimicrob Chemother 2009;63(6):1101-7 (PubMed)
[8]: IDSA Guidelines for Complicated Infections, 2010/2021 updates